Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neutropenia 2Breast Neoplasms 2

Interventions

pegfilgrastim 13Filgrastim 8Cyclophosphamide 3liposomal amphotericin B 2eflapegrastim 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Levofloxacin 2Idarubicin 2Fluconazole 2Etoposide 2Docetaxel 2Cytarabine 2Ciprofloxacin 2Cefepime 2Caspofungin 2Amsacrine 2pegylated granulocyte colony-stimulating factor 1ceftobiprole medocaril 1Vancomycin 1Tretinoin 1Thioguanine 1Radiotherapy 1Psychiatric Rehabilitation 1MYL-1401H 1Lithium Carbonate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Daunorubicin 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neutropenia × eflapegrastim × Clear all
NCT02643420 2022-03-02

ADVANCE

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
406 enrolled 19 charts
Breast

Breast Neoplasms, Neutropenia

NCT02953340 2022-03-02

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
237 enrolled 18 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡